Results 11 to 20 of about 760 (154)

Sulbactam/Durlobactam: First Approval [PDF]

Drugs, 2023
Sulbactam/durlobactam (XACDURO®), is a co-packaged antibacterial product that has been developed by Entasis Therapeutics Inc. for the treatment of infections caused by Acinetobacter baumannii-calcoaceticus complex (ABC). Coadministration of durlobactam (a β-lactamase inhibitor with potent activity against a broad range of serine β-lactamases) with ...
Susan Keam (4873372)
openaire   +3 more sources

In vitro activity of sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii and mechanisms of resistance [PDF]

Journal of Global Antimicrobial Resistance, 2022
Multidrug-resistant Acinetobacter baumannii (MDR-Ab), particularly strains producing oxacillinase (OXA)-type carbapenemases, have rapidly emerged in health care settings as a frequent cause of serious infections with limited treatment options. This study evaluated the in vitro activity of sulbactam (SUL) combined with durlobactam (DUR) against a ...
Findlay, J., Poirel, L., Bouvier, M., Nordmann, P.   +3 more
openaire   +5 more sources

The role of sulbactam-durlobactam in treating carbapenem-resistant Acinetobacter infections [PDF]

Current Opinion in Infectious Diseases
Purpose of review Infections caused by multidrug-resistant Acinetobacter baumannii present a significant global health challenge. Available treatment options are limited and frequently constrained by unfavourable safety and pharmacokinetic profiles.
Bassetti, Matteo, Giacobbe, Daniele Roberto, Castaldo, Nadia, Vena, Antonio   +3 more
openaire   +4 more sources

Sulbactam–durlobactam for infections caused by Acinetobacter baumannii–calcoaceticus complex [PDF]

The Lancet Infectious Diseases, 2023
Giuliano S., Sbrana F., Tascini C.
openaire   +4 more sources

Sulbactam-Durlobactam for Carbapenem-Resistant <i>Acinetobacter baumannii-calcoaceticus</i> Complex. [PDF]

Pathogens
Carbapenem-resistant Acinetobacter baumannii infections pose a significant challenge due to their severity and the poor prognoses they often result in, particularly in cases where there are risk factors present. The United States (US) Centers for Disease Control and Prevention (CDC) identified carbapenem-resistant Acinetobacter baumannii (CRAB ...
Nappi F.
europepmc   +2 more sources

In vitro activity of cefepime/zidebactam against sulbactam/durlobactam-susceptible and -resistant Acinetobacter baumannii clinical isolates. [PDF]

J Antimicrob Chemother
Objectives: To evaluate the in vitro activity of cefepime in association with a β-lactamase inhibitor (enmetazobactam) or β-lactam enhancer (BLE), zidebactam, against carbapenem-resistant Acinetobacter baumannii (CRAB) strains susceptible or resistant to
Tascini C, Bianco G, Bonomo RA, Gaibani P.   +3 more
europepmc   +2 more sources

Sulbactam-Durlobactam in the Treatment of Multidrug-Resistant <i>Acinetobacter baumannii:</i> A Narrative Review. [PDF]

Antibiotics (Basel)
The increasing prevalence of infections caused by multidrug-resistant (MDR) Gram-negative bacteria represents a major global public health challenge. Among hospital-acquired infections (HAIs), ventilator-associated pneumonia (VAP) caused by non-fermenting Gram-negative pathogens, particularly the Acinetobacter baumannii-calcoaceticus complex, it is ...
Viscardi S, Lipska P, Niezgódka P, Duda-Madej A.   +3 more
europepmc   +3 more sources

New Perspectives on Antimicrobial Agents: Sulbactam-durlobactam. [PDF]

Antimicrob Agents Chemother
ABSTRACT Infections due to Carbapenem-resistant Acinetobacter baumannii (CRAB) are a significant burden and are associated with devastating outcomes. Subsequently, CRAB is recognized as an urgent threat to human health by the United States (US) Centers for Disease Control ...
Pogue JM, Harrington J, Wangchinda W, Kaye KS.   +3 more
europepmc   +3 more sources

In Vitro Activity of Sulbactam-Durlobactam against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates: A Multicentre Report from Italy [PDF]

, 2022
In the present study, the in vitro activity of the sulbactam-durlobactam (SUL-DUR) combination was evaluated against 141 carbapenem-resistant A. baumannii (CRAb) clinical strains collected from six Italian laboratories.
Pompilio, Arianna, Mario Salmeri, Perilli, Mariagrazia, Giulia De Angelis, Cortazzo, Venere, Salmeri, Mario, Di Bella, Stefano, Segatore, Bernardetta, Venere Cortazzo, Stefano Di Bella, Luigi Principe, Giovanni Alloggia, Alessandra Piccirilli, Sabrina Cherubini, Cherubini, Sabrina, Fazii, Paolo, Aurora Piazza, Maria Lina Mezzatesta, Visaggio, Daniela, Visca, Paolo, Paolo Fazii, Paolo Visca, Migliavacca, Roberta, Meroni, Elisa, Daniela Visaggio, Roberta Migliavacca, Alloggia, Giovanni, Mariagrazia Perilli, Arianna Pompilio, Bernardetta Segatore, De Angelis, Giulia, Elisa Meroni, Principe, Luigi, Piazza, Aurora, Piccirilli, Alessandra, Mezzatesta, Maria Lina   +35 more
core   +3 more sources

Sulbactam-durlobactam plus ceftriaxone dosing and novel treatment regimens for <i>Mycobacterium abscessus</i> lung disease. [PDF]

Antimicrob Agents Chemother
ABSTRACT The guideline-based therapy achieves sputum culture conversion rates in 20%–34% of patients with Mycobacterium abscessus (MAB) lung disease (LD). Double-β-lactam combinations have been proposed to improve cure based on
Singh S, Shrivastava A, Boorgula GD, Long MC, Robbins B, McShane PJ, Gumbo T, Srivastava S.   +7 more
europepmc   +3 more sources